Hi All,
Now researchers report that underexpression of a special gene set - the JNK gene set - perhaps may identify patients likely to respond to Ezatiostat (TLK199).
C-Jun NH2-terminal kinase (JNK) is implicated in transformation to cancer.
The abstract is complicated – you will find the important info in this sentence:
The expression data confirms that patients whose pre-therapy marrow shows under-expression of the JNK gene set are precisely those who benefit from this drug therapy and those patients who already over-express these genes are unlikely to respond.
http://ash.confex.com/ash/2011/webpr...aper37656.html
This kind of research is very important and we hope they at last will find out the best treatment for all MDS patients.
Patients with the 5q- will often respond to Revlimid, patients with lower DNA methylation of the WT1 gene will perhaps have a better response to Vidaza and patients with underexpression of the JNK gene set will eventually respond to Ezatiostat.
Kind regards
Birgitta-A